A new drug is now available in Australia for men battling the most deadly form of advanced prostate cancer.
The Therapeutic Goods Administration (TGA) has registered the drug darolutamide (sold as Nubeqa) for men with advanced metastatic hormone-sensitive prostate cancer, the Herald Sun reports. The drug is taken as a tablet twice daily and works by starving cancer cells of the hormones they need to grow and divide.
The drug has been approved for use as a ‘triplet therapy and is taken in combination with chemotherapy and a hormone therapy injection.
More than 1300 men worldwide, including patients from Australia, took part in the ARASENS trial published in the New England Journal of Medicine a year ago. Further promising results were published last month.
Prostate cancer is the most commonly diagnosed cancer in Australia.
.
